Clinical Trial Update: Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lusutrombopag for immune thrombocytopenia has completed, assessing its potential to raise platelet counts in patients with ITP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenia

Drugs mentioned

• lusutrombopag (lusutrombopag)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 2 | Status: COMPLETED